Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of EuCorVac-19 in Healthy Adults
NCT04783311Phase 2Completed
- Sponsor
- EuBiologics
- Start
- Feb 2021
- Primary completion
- Oct 2021
- Modality
- Targeted Liposomes, Recombinant Protein Vaccines, Stealth (PEGylated) Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of eucorvac-19 in coronavirus disease 2019 (COVID-19), sponsored by EuBiologics. Started Feb 2021; status: completed.
02
Drugs
eucorvac-19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04783311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04783311.